USPTO Art Unit 1638 Prosecution Statistics

Art Unit Information

Art Unit: 1638
Group: 1630
Tech Center: 1600
Total Cases: 13,872
Last Active: April 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19200761Circular RNA CompositionsMay 2025November 2025Allow610YesNo
19192918GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTESApril 2025December 2025Allow820NoNo
19171465COMPOSITIONS AND METHODS FOR THE TREATMENT OF VEN/AZA RESISTANT ACUTE MYELOID LEUKEMIAApril 2025June 2025Allow200NoNo
19097114AAV CAPSID VARIANTS AND USES THEREOFApril 2025June 2025Allow310NoNo
19070308Method and Apparatus for Producing CAR T CellsMarch 2025November 2025Allow921YesNo
19046845METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIAFebruary 2025October 2025Allow820YesNo
19043304PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOFJanuary 2025July 2025Allow510NoNo
19042240INTEGRATIVE PLASMIDJanuary 2025February 2026Allow1220NoNo
18970024HEPATITIS E VIRUS-LIKE PARTICLES (VLPS) DERIVED FROM CONSENSUS SEQUENCESDecember 2024December 2025Allow1310YesNo
18964137PLASMID ENCODING A DNAse-I AND Fc FUSION PROTEINNovember 2024August 2025Allow820NoNo
18964119PLASMID ENCODING A TLR9 AND Fc FUSION PROTEINNovember 2024October 2025Allow1120NoNo
18964155PLASMID ENCODING A NGF AND Fc FUSION PROTEINNovember 2024December 2025Allow1220NoNo
18964162PLASMID ENCODING AN INSULIN PEPTIDE AND Fc FUSION PROTEINNovember 2024December 2025Allow1220NoNo
18948331COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERYNovember 2024October 2025Allow1110YesNo
18933687GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTESOctober 2024June 2025Allow720NoNo
18900968METHOD FOR EFFICIENTLY INFECTING HUMAN NATURAL KILLER CELLS AND OTHER IMMUNE CELLS WITH PSEUDOVIRUSSeptember 2024August 2025Allow1020YesNo
18895296IMMUNE CELLS DEFECTIVE FOR SUV39H1September 2024April 2025Allow720YesNo
18886134LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOFSeptember 2024December 2024Allow310NoNo
18821057DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024February 2025Allow610NoNo
18820609DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024February 2025Allow510NoNo
18821068DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024February 2025Allow610NoNo
18820652DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024March 2025Allow710YesNo
18796740GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPYAugust 2024December 2024Allow410NoNo
18777787COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTJuly 2024February 2025Allow710NoNo
18777187COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTJuly 2024January 2025Allow610NoNo
18773146COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJuly 2024January 2025Allow610NoNo
18765147COMPOSITIONS AND METHODS FOR DELIVERING MOLECULESJuly 2024September 2025Allow1521NoNo
18757141AAV CAPSID VARIANTS AND USES THEREOFJune 2024March 2025Allow811NoNo
18672944COMPOSITIONS AND METHODS OF EXPANSION OF T CELL POPULATIONSMay 2024December 2025Abandon1801NoNo
18649317RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEApril 2024November 2024Allow610NoNo
18633883TRANSGENIC RAINBOW SHARKApril 2024October 2025Allow1811YesNo
18620748Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and LeukemiasMarch 2024October 2024Allow720YesNo
18596451VACCINATION WITH mRNA-CODED ANTIGENSMarch 2024May 2024Allow210NoNo
18594693MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINASE LIKE 7 (PTK7) AND IMMUNE CELLS EXPRESSING SUCHMarch 2024January 2026Abandon2221NoNo
18583191CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATIONFebruary 2024January 2026Allow2340YesNo
18583147CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATIONFebruary 2024July 2025Allow1620YesNo
18582222PLASMID ENCODING A TLR3 AND Fc FUSION PROTEINFebruary 2024August 2025Allow1732YesNo
18415134COMPUTER-BASED SYSTEMS FOR CONTROLLING AND MONITORING METABOLIC RATE AND ENVIRONMENTAL FACTORS OF AT LEAST ONE BIOREACTOR AND METHODS OF USE THEREOFJanuary 2024December 2025Abandon2311YesNo
18413653LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOFJanuary 2024June 2024Allow510NoNo
18397317Enhanced Microbial Production of Biosurfactants and Other Products, and Uses ThereofDecember 2023December 2025Allow2410YesNo
18526459GENERATING ATRIAL AND VENTRICULAR CARDIOMYOCYTE LINEAGES FROM HUMAN PLURIPOTENT STEM CELLSDecember 2023July 2025Abandon1901NoNo
18521129Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses ThereofNovember 2023January 2026Abandon2610NoNo
18513069CONSTRUCTION METHOD AND APPLICATION OF OVARIAN GRANULOSA CELL LINE OF ONCORHYNCHUS MYKISSNovember 2023February 2025Abandon1520NoNo
18511513CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASENovember 2023March 2026Allow2810NoNo
18511290AAV CAPSIDS WITH INCREASED TROPISM TO BRAIN TISSUENovember 2023October 2025Allow2321YesNo
18508998METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIANovember 2023November 2025Abandon2421NoNo
18560539THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR BONE AND SOFT TISSUE TUMORSNovember 2023January 2025Allow1410YesNo
18501269WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND METHODS THEREOFNovember 2023June 2024Allow700NoNo
18501837GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTESNovember 2023August 2024Allow1021NoNo
18497798DETERMINISTIC MECHANOPORATION FOR CELL ENGINEERINGOctober 2023July 2025Abandon2111NoNo
18485178COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTOctober 2023May 2024Allow710YesNo
18377827HELPER PLASMID AND METHOD FOR PREPARING RECOMBINANT ADENO-ASSOCIATED VIRUSOctober 2023September 2025Allow2310NoNo
18481955NANOCAGED ENZYMES WITH ENHANCED CATALYTIC ACTIVITY AND INCREASED STABILITYOctober 2023February 2026Allow2810NoNo
18474533Cross-Species Compatible Adeno-Associated Virus Compositions and Methods of Use ThereofSeptember 2023March 2024Allow510NoNo
18372868ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF PROGRANULIN ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERSSeptember 2023February 2026Abandon2911NoNo
18468652CARDIAC CELL REPROGRAMMING WITH MYOCARDIN AND ASCL1September 2023July 2024Allow1011NoNo
18550503SMART EXOSOMES FOR ACTIVE PDAC TARGETING AND EVADING MONONUCLEAR PHAGOCYTOTIC SYSTEMSeptember 2023May 2024Allow810NoNo
18463907USE OF CD33CAR MODIFIED HIGH AFFINITY NK CELLS (T-HANK) TO REDUCE MYELOID-DERIVED SUPPRESSOR CELLS SUPPRESSOR ACTIVITY (OR REDUCE NEGATIVE IMPACT ON NK CELL ACTIVITY)September 2023October 2024Allow1311NoNo
18242731METHODS RELATING TO INTESTINAL ORGAN-ON-A-CHIPSeptember 2023October 2024Allow1410YesNo
18461866POTENCY ASSAYSeptember 2023December 2024Abandon1510NoNo
18459533CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell TherapySeptember 2023October 2025Abandon2510NoNo
18459302METHODS OF USE FOR CAR T CELLSAugust 2023November 2024Allow1520YesNo
18458744COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTAugust 2023January 2024Allow510NoNo
18458752COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTAugust 2023May 2024Allow820YesNo
18458062MULTIEPITOPE VACCINE CASSETTESAugust 2023November 2025Abandon2610NoNo
18450896MULTIPOTENT ADULT STEM CELLS: CHARACTERIZATION AND USEAugust 2023November 2025Abandon2721YesNo
18450549HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELLAugust 2023June 2025Abandon2231YesNo
18448421REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEURAL INJURY CAUSED BY DISRUPTION OF BLOOD FLOWAugust 2023October 2025Abandon2610NoNo
18358358MUTATED POLYPEPTIDES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOFJuly 2023November 2024Allow1610YesNo
18339917TRAIT SELECTION IN AVIANSJune 2023October 2025Abandon2820NoNo
18339157METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITYJune 2023November 2023Allow500NoNo
18010885CORONAVIRUS PSEUDOVIRUS PACKAGING SYSTEM, PACKAGING METHOD THEREFOR, AND APPLICATION OF CORONAVIRUS PSEUDOVIRUS IN EVALUATING DISINFECTION EFFICACYJune 2023December 2025Allow3600NoNo
18267340MICE EXPRESSING HUMANIZED FC ALPHA RECEPTORSJune 2023March 2026Allow3310YesNo
18204999METHOD FOR STERILISING A PLATELET LYSATEJune 2023March 2025Allow2220YesNo
18255221SUSPENSION MODE SEED TRAIN DEVELOPMENT FOR ADHERENT CELLSMay 2023December 2025Allow3010YesNo
18203222NANOHELIX-SUBSTRATE COMPLEX FOR CONTROLLING MACROPHAGE BEHAVIOR, PREPARATION METHOD THEREOF, AND METHOD OF CONTROLLING ADHESION AND POLARIZATION OF MACROPHAGE BY USING THE SAMEMay 2023August 2024Allow1510YesNo
18321481CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLSMay 2023January 2026Allow3210NoNo
18320244Methods for Generation for Pluripotent and Multipotent CellsMay 2023November 2024Abandon1801NoNo
18318507METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULESMay 2023January 2024Allow810NoNo
18318566CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATIONMay 2023July 2024Allow1450YesNo
18316461GENETICALLY MODIFIED MICE HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENEMay 2023March 2026Allow3410NoNo
18252498ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN CHANDELIER CELLSMay 2023February 2026Allow3301NoNo
18309466ETV2 AND USES THEREOFApril 2023December 2024Abandon2010NoNo
18250609Barcoded Cells Engineered With Heterozygous Genetic DiversityApril 2023February 2025Abandon2120NoNo
18033536HYDROGEL COMPOSITIONS AND METHODS OF USE THEREOFApril 2023March 2026Allow3410NoNo
18305876Use of CDK Inhibitors to Enhance Growth and Self-Renewal of Progenitor CellsApril 2023January 2026Abandon3311NoNo
18136774REGULATION OF TRANSLATION OF EXPRESSED GENESApril 2023February 2026Allow3400NoNo
18301164METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERSApril 2023September 2025Abandon2901NoNo
18248967IMPROVED ADENO-ASSOCIATED VIRUS (AAV) VECTOR AND USES THEREFORApril 2023December 2025Allow3200NoNo
18297347PLAKOPHILLIN-2 GENE THERAPY METHODS AND COMPOSITIONSApril 2023November 2025Allow3100YesNo
18030730THERAPEUTIC ADENO-ASSOCIATED VIRUS DELIVERY OF FUKUTIN RELATED PROTEIN (FKRP) FOR TREATING DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21 (LGMD21)April 2023January 2026Allow3301NoNo
18296923Methods of Preserving Mesenchymal Stem CellsApril 2023February 2026Allow3510NoNo
18295152LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYApril 2023December 2023Allow810YesNo
18295150LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYApril 2023December 2023Allow810YesNo
18295159LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYApril 2023December 2023Allow810YesNo
18192492METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163March 2023March 2025Allow2420NoNo
18191163Chimeric Antigen ReceptorMarch 2023September 2025Abandon3001NoNo
18125879DEVICES AND SYSTEMS FOR MIMICKING HEART FUNCTIONMarch 2023December 2025Allow3300NoNo
18188854Method for Mosquito ControlMarch 2023September 2024Allow1811YesNo
18246468COMPOUNDS AND METHODS FOR REDUCING APOE EXPRESSIONMarch 2023September 2025Allow3000NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1638.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
94
Examiner Affirmed
54
(57.4%)
Examiner Reversed
40
(42.6%)
Reversal Percentile
86.0%
Higher than average

What This Means

With a 42.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
928
Allowed After Appeal Filing
337
(36.3%)
Not Allowed After Appeal Filing
591
(63.7%)
Filing Benefit Percentile
72.9%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 36.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1638 - Prosecution Statistics Summary

Executive Summary

Art Unit 1638 is part of Group 1630 in Technology Center 1600. This art unit has examined 13,872 patent applications in our dataset, with an overall allowance rate of 76.6%. Applications typically reach final disposition in approximately 29 months.

Comparative Analysis

Art Unit 1638's allowance rate of 76.6% places it in the 51% percentile among all USPTO art units. This art unit has an above-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1638 receive an average of 1.46 office actions before reaching final disposition (in the 19% percentile). The median prosecution time is 29 months (in the 57% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.